KATHRYN MARTIN: Open Payments
NPI 1851620116 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$150 in 8 payments from 8 companies in 2025. Trend: 2023 $364 · 2024 $68 · 2025 $150
Food & beverage: $150
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Merck Sharp & Dohme LLC | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $15 |
| Myriad Genetic Laboratories, Inc. | 1 | $14 |
Products named: IMFINZI, ICLUSIG, KEYTRUDA, DATROWAY, LYNOZYFIC, DANZITEN, Nubeqa, MYRISK.
Industry payments across TX — which companies pay providers there.
